On February 2, 2024, Zhejiang Anglikang Pharmaceutical Co., Ltd. (stock abbreviation: Anglikang, stock code: 002940) and Affinity(Shanghai) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Affinity") held the signing ceremony of the Strategic Cooperation Agreement in Anglikang’s headquarter building. Dr. Cheng Liu, Founder, CEO & Co-CMO of Affinity, Ji Ma, Chairman of Hongfu Investment, and Nanping Fang, Chairman of Anglikang, attended the event.  

Guogang Zheng, General Manager of Anglikang, mentioned during the signing ceremony: "Anglikang is a pharmaceutical company with a heritage of over 60 years, and Affinity is a world-leading biopharma focusing on Tumor Microenvironment-Activated technology platform. Anglikang is entering into innovative drugs development, and both parties share the same concept of developing innovative drugs to address the huge unmet clinical needs. We hope that through the strong alliance and technological complementation of the two companies, we can empower new energies into the development of China’s healthcare industry."

Dr. Cheng Liu, Founder, CEO & Co-CMO of Affinity, said: “The two parties have opened a new chapter of cooperation based on Affinity’s Tumor Microenvironment-Activated platform, and by leveraging each party’s advantages, we can accelerate the research and development process of innovative drugs and transform innovative results into applications faster, bringing in greater values to patients. It is based on this consensus that Affinity and Anglikang can work together to jointly promote innovative pharmaceutical products and contribute to the benefits of the whole society.”